Skip To Main Content

Deze website is alleen bedoeld voor zorgverleners van België en Luxemburg.

Odyssey Outcomes Education

Praluent – Effect of Alirocumab on Mortality after ACS | Sub-analysis of the Odyssey Outcome Study

Gerelateerde paginas

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Preventive Cardiology: Key Insights from Professor Michal Vrablik

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262